Vol 55, No 1 (2021)
Letter to the Editors
Published online: 2021-01-29

open access

Page views 1251
Article views/downloads 2345
Get Citation

Connect on Social Media

Connect on Social Media

Lacosamide and myoclonic seizures: what is the risk of aggravation?

Magdalena Bosak1, Kamil Wężyk2, Agnieszka Słowik1
Pubmed: 33512706
Neurol Neurochir Pol 2021;55(1):107-109.


Not available

Article available in PDF format

View PDF Download PDF file


  1. Vossler DG, Knake S, O'Brien TJ, et al. SP0982 trial investigators. Efficacy and safety of adjunctive lacosamide in the treatment of primary generalised tonic-clonic seizures: a double-blind, randomised, placebo-controlled trial. J Neurol Neurosurg Psychiatry. 2020; 91(10): 1067–1075.
  2. Chaves J, Sander JW. Seizure aggravation in idiopathic generalized epilepsies. Epilepsia. 2005; 46 Suppl 9: 133–139.
  3. Wężyk K, Słowik A, Bosak M. Predictors of remission in patients with epilepsy. Neurol Neurochir Pol. 2020; 54(5): 434–439.
  4. Swaminathan A, Kapoor S. A case report of exacerbation of myoclonus in idiopathic generalized epilepsy from use of lacosamide. Neurology. 2015; 84 (14 Suppl.) Abstracts: AAN 67th Annual Meeting.
  5. Birnbaum D, Koubeissi M. Unmasking of myoclonus by lacosamide in generalized epilepsy. Epilepsy Behav Case Rep. 2017; 7: 28–30.
  6. Belcastro V, Arnaboldi M, Taborelli A, et al. Induction of epileptic negative myoclonus by addition of lacosamide to carbamazepine. Epilepsy Behav. 2011; 20(3): 589–590.
  7. Abarrategui B, García-García ME, Toledano R, et al. Lacosamide for refractory generalized tonic-clonic seizures of non-focal origin in clinical practice: A clinical and VEEG study. Epilepsy Behav Case Rep. 2017; 8: 63–65.
  8. Wechsler RT, Yates SL, Messenheimer J, et al. Lacosamide for uncontrolled primary generalized tonic-clonic seizures: An open-label pilot study with 59-week extension. Epilepsy Res. 2017; 130: 13–20.